OPTN - オプティノ―ズ (OptiNose Inc.) オプティノ―ズ

 OPTNのチャート


 OPTNの企業情報

symbol OPTN
会社名 OptiNose Inc (オプティノ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オプティノーズ(OptiNose Inc.)は製薬会社である。同社は、耳、鼻、咽喉、またはENT、及びアレルギーの専門家によって治療された患者のための製品の開発・商品化に従事する。同社の製品候補には、XHANCE(鼻ポリープ)、チャンス(慢性副鼻腔炎)OPN-300、OPN-021などがある。主力製品であるXHANCE(プロピオン酸フルチカゾン)の鼻スプレーは、鼻ポリープを伴う慢性鼻副鼻腔炎の治療用局所的に作用し強力な抗炎症性コルチコステロイドを送達するために、呼吸動力呼気供給システム(EDS)を利用する。XHANCEは、炎症の原発部位に薬物を送達することができるため、この疾患の治療基準の一部となる可能性を有する差別化された臨床プロファイルを有する。   オプティノ―ズは米国の専門医薬品企業。主に耳鼻咽喉科の疾患に対する治療薬の開発・商業化に従事する。同社製品には鼻ポリ―プの有無に関わらず慢性鼻副鼻腔炎の治療用に、局所作用の抗炎症性コルチコステロイドを送達する呼気供給システムの「XHANCE」を含む。また、偏頭痛の治療薬「AVP-825」を販売する。本社所在地はペンシルベニア州ヤ―ドレ―。   Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S. and Norway.
本社所在地 1020 Stony Hill Road Suite 300 Yardley PA 19067 USA
代表者氏名 Joseph C. Scodari ジョセフ・C.スコダリ
代表者役職名 Independent Chairman of the Board
電話番号 +1 267-364-3500
設立年月日 40299
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 82人
url www.optinose.com
nasdaq_url https://www.nasdaq.com/symbol/optn
adr_tso
EBITDA EBITDA(百万ドル) -84.65000
終値(lastsale) 10.66
時価総額(marketcap) 439411958.44
時価総額 時価総額(百万ドル) 469.50300
売上高 売上高(百万ドル) 2.13900
企業価値(EV) 企業価値(EV)(百万ドル) 296.65100
当期純利益 当期純利益(百万ドル) -92.61300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 OptiNose Inc revenues increased from $0K to $2.1M. Net loss applicable to common stockholders increased from $24.5M to $55.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling general and administrative increase from $6.1M to $46.2M (expense) Interest expense increase from $862K to $4.5M (expense).

 OPTNのテクニカル分析


 OPTNのニュース

   OptiNose Inc Shares Close the Day 17.3% Higher - Daily Wrap  2022/01/04 13:12:47 Kwhen Finance
OptiNose Inc (OPTN) shares closed today 17.3% higher than it did at the end of yesterday. The stock is currently up 17.3% year-to-date, down 54.1% over the past 12 months, and down 90.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.91 and as low as $1.55 this week.Shares closed 60.8% below its 52-week high and 30.1% above its 52-week low.Trading volume this week was 12.4% lower than the 10-day average and 15.3% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 428.4% The company's stock price performance over the past 12 months lags the peer average by 521.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   State Street Corp Sells 483,816 Shares of OptiNose, Inc. (NASDAQ:OPTN)  2021/12/09 09:52:47 Dakota Financial News
State Street Corp lessened its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN) by 83.7% during the second quarter, Holdings Channel.com reports. The firm owned 93,995 shares of the companys stock after selling 483,816 shares during the quarter. State Street Corps holdings in OptiNose were worth $292,000 at the end of the most recent quarter. Several []
   OptiNose (NASDAQ:OPTN) Downgraded by Zacks Investment Research  2021/12/09 09:02:42 ETF Daily News
OptiNose (NASDAQ:OPTN) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or [] The post OptiNose (NASDAQ:OPTN) Downgraded by Zacks Investment Research appeared first on ETF Daily News .
   OptiNose (NASDAQ:OPTN) Raised to Buy at Zacks Investment Research  2021/12/07 06:42:41 Transcript Daily
Zacks Investment Research upgraded shares of OptiNose (NASDAQ:OPTN) from a hold rating to a buy rating in a report issued on Saturday, Zacks.com reports. They currently have $1.75 price target on the stock. According to Zacks, OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated []
   OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Northern Trust Corp  2021/12/05 09:10:45 ETF Daily News
Northern Trust Corp cut its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN) by 81.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 67,965 shares of the companys stock after selling 307,422 shares during the period. Northern Trust Corp owned approximately 0.13% of OptiNose worth [] The post OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Northern Trust Corp appeared first on ETF Daily News .
   Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/08/25 21:00:00 Intrado Digital Media
YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose , Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
   OptiNose EPS misses by $0.02, misses on revenue  2021/08/11 11:27:41 Seeking Alpha
   Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights  2021/08/11 11:00:00 Intrado Digital Media
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020
   Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis  2021/07/30 12:00:00 Intrado Digital Media
Company Expects Top-Line Results in First Quarter 2022
   Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million  2021/07/28 12:00:00 Intrado Digital Media
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020
   Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis  2021/07/30 12:00:00 Intrado Digital Media
Company Expects Top-Line Results in First Quarter 2022
   Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million  2021/07/28 12:00:00 Intrado Digital Media
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020
   Global Corticosteroid Nasal Spray Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Pfizer, Sanofi, Kurve Technology, Aegis Therapeutics, OptiNose, GlaxoSmithKline, Merck, Marina Biotech  2021/07/23 16:44:04 Jumbo News
The report on Global Corticosteroid Nasal Spray Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
   OptiNose: Growing Sales Make The Current Market Cap Look Very Low  2021/07/19 03:56:35 Seeking Alpha
   OptiNose Inc Shares Near 52-Week Low - Market Mover  2021/07/17 16:05:42 Kwhen Finance
OptiNose Inc (OPTN) shares closed today at 1.8% above its 52 week low of $2.80, giving the company a market cap of $151M. The stock is currently down 31.2% year-to-date, down 41.0% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 51.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 227.0% The company's stock price performance over the past 12 months lags the peer average by 161.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オプティノ―ズ OPTN OptiNose Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)